$QURE

Kaye Jack sold $54K of QURE

Kaye Jack sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Kaye Jack
Published Jun 12, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

Discloses a director’s open-market sale of 1,993 shares at $27.06 on 2026-06-11; no 10b5-1 plan is indicated.

02

Market read

Primarily sentiment/positioning information; not a new fundamental catalyst.

03

What to watch

Traders may over-weight single insider sales; without follow-on buys/sells, volume/price context, or linkage to a broader corporate event, the signal is likely noise.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

Director Kaye Jack filed an SEC Form 4 selling 1,993 QURE shares in an open-market transaction on 2026-06-11 for ~$53.9K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless accompanied by other news.

Evidence & confidence

The filing is a small, open-market sale by a director with no 10b5-1 plan stated; however, insider sales are common and the article provides no new company-specific operational/regulatory catalyst.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide read-across provided.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could mean the sale was discretionary, but the disclosed size (~$54K) is still small relative to typical market impact.

Key entities

  • Kaye Jack

    Director of uniQure N.V. who sold 1,993 shares via open-market sale.

  • uniQure N.V.

    Company whose shares were sold; insider transaction filed on SEC EDGAR.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.